Charco Neurotech, founded at Imperial, will work with Queen Mary University of London, to test its device for alleviating the symptoms of Parkinson’s.
Imperial startup joins forces with QMUL on medtech to help Parkinson’s sufferers
More From the Press
Parkinson’s Insights share our latest clinical publication and transitional journey towards Class IIa medical device certification
Charco Neurotech prepares to relaunch CUE1+ following trial findings and medical device certification. Read article
Read more
Parkinson’s UK share our latest clinical publication
Results from a clinical trial of CUE1+, a chest-mounted device, has shown it’s well tolerated by people with…
Read moreCharco Neurotech announces publication of a pilot RCT, with data highlighting that the CUE1+ is safe, well tolerated, with encouraging signals for motor symptom relief in people with Parkinson’s
A double-blind, placebo-controlled study of 50 people with Parkinson’s, published in Parkinson’s Disease, part of the Nature Portfolio, is the first…
Read more